PPT-Current Practice of Hematopoietic

Stem Cell Transplant for Primary Immunodeficiencies Nancy Bunin MD Medical Director Cell Therapy and Transplant Program Division of Oncology To DISCUSS SCID Newborn Screening Transplant controversies. 1 Hematopoietic and Lymphoid Neoplasm Coding ManualEffective with Cases Diagnosed 1/1/2010 and ForwardPublished January 2015In Appreciation Editors: Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEERMarga Adapted from {. Gazit. R, . Weissman. IL and Rossi DJ 2008}. HSC. MPP. Mouse. Lineage. -/low. Sca1. +. cKit. +. flk2. -. CD34. -. CD48. -. CD150. +. Human. Lineage. -/low. CD90. +. CD45RA. -. CD34. Location of Centers Participating. in the CIBMTR 2017*. Annual Number of . HCT. Recipients in the US by Transplant Type. Allogeneic HCT Recipients in the US, by Donor Type . Allogeneic HCT Recipients in the US, by Donor Type. Location of Centers Participating. in the CIBMTR 2015. Annual Number of Transplant Recipients in the US by Transplant Type. Allogeneic Transplant Recipients in the US, by Donor Type. Cumulative Plot of Transplant Recipients in the US by Transplant Type. Location of Centers Participating. in the CIBMTR 2014. Annual Number of Transplant Recipients in the US by Transplant Type. Transplant Recipients in the US, by Transplant and Donor Type. Cumulative Plot of Transplant Recipients in the US by Transplant Type. Munir Gharaibeh, MD, PhD, MHPE. Department of Pharmacology. Faculty of Medicine. October 2019. Cancer drugs—cell cycle. Anticancer Drugs Targets. Drugs used in Leukemias, Lymphomas. Antitumor antibiotics:. D. Craig Hooper, PhD, FNAI. Professor of Cancer Biology, SKCC, TJU. DouglasC.Hooper@Jefferson.edu. Therapeutic Modalities. Cancer immunotherapy. Hematologic disorders (non-malignant). Regenerative medicine. Hematopoietic. stem cell. Neutrophils. Eosinophils. Basophils. Monocytes. Platelets. Red cells. Myeloid. progenitor. Lymphoid. progenitor. B-lymphocytes. T-lymphocytes. Plasma. cells. germinal center. 41. Learning Objectives—Level I. At the end of this unit of study, the student should be able to:. Define . chromosome. and . mitosis. .. List the basic steps of cytogenetic analysis, and select the most appropriate type of specimen for analysis of suspected constitutional and neoplastic (acquired) disorders.. 23. Learning Objectives—Level I. At the end of this unit of study, the student should be able to:. Define and differentiate the terms . neoplasm. and . malignant. and identify hematopoietic disorders that can be included in each category.. Sigma brand products are sold through Sigma-Aldrich, Inc. Sigma-Aldrich, Inc. warrants that its products conform to the information contained in this and other Sigma-Aldrich publicationmust determine ®. Hematopoietic Stem Cells (HSCs) are capable of developing into any blood cell lineage. They develop in the bone marrow.. A small percentage of HSCs interacted with the . endosteal. niche, SNO cells, and osteoblasts.. Myeloid. Lymphoid. Histiocytic. Myeloid . neoplasms. (1) . Myeloproliferative. . neoplasms. (2) . Myelodysplastic. syndromes. (3) Acute myeloid leukemia. Features:. Recurrent genetic mutations. Increased bone marrow cellularity. Def: the administration of hematopoietic stem cells from any source (ex: bone marrow, peripheral blood, umbilical cord blood) to reconstitute the bone marrow.. The Nobel Prize, 1990. E. Donnall Thomas .